Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-03-14 DOI:10.1002/cam4.70673

Zerubbabel K. Asfaw, Tirone Young, Cole Brown, Mehek Dehdia, Lily Huo, Kunal K. Sindhu, Stanislav Lazarev, Robert Samstein, Sheryl Green, Isabelle M. Germano

{"title":"Transforming Brain Tumor Care: The Global Impact of Radiosurgery in Multidisciplinary Treatment Over Two Decades","authors":"Zerubbabel K. Asfaw, Tirone Young, Cole Brown, Mehek Dehdia, Lily Huo, Kunal K. Sindhu, Stanislav Lazarev, Robert Samstein, Sheryl Green, Isabelle M. Germano","doi":"10.1002/cam4.70673","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Stereotactic radiosurgery, a minimally invasive treatment delivering high doses of radiation to a well-defined target, has transformed interdisciplinary treatment paradigms since its inception. This study chronicles its adoption and evolution for brain cancer and tumors globally.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic literature review of SRS-focused articles from 2000 to 2023 was conducted. Literature impact was evaluated using citation counts and relative citation ratio scores. Extracted data were dichotomized between US and international publications.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Out of 5424 articles eligible, 538 met inclusion criteria reporting on 120,756 patients treated with SRS for brain cancer and tumors since 2000. Over time, publication rates grew significantly (<i>p</i> = 0.0016), with 56% of principal investigators based in the United States. Clinical articles accounted for 87% of the publications, with the remainder focused on technological advances. Relative to international studies, US publications had larger median samples (74 vs. 58, <i>p</i> = 0.012), higher median citations (30 vs. 19, <i>p</i> < 0.0001) and higher relative citation ratio scores (1.67 vs. 1.2, <i>p</i> < 0.00001). Gamma Knife and LINAC had roughly equal representation in US and international publications. Neurosurgery specialists authored more Gamma Knife-based articles, and radiation oncology specialists authored more LINAC-based papers (<i>p</i> < 0.0001). The most treated tumors were metastases (58%), skull base tumors (35%), and gliomas (7%). Radiographic control was achieved in 82% of metastatic tumor cases, with a 12% median complication rate.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>SRS has been widely adopted both nationally and globally and continues to be a growing field. This study corroborates the clinical efficacy of SRS and reinforces its critical role in the multidisciplinary treatment of patients with brain tumors and cancer.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 6","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70673","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70673","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Stereotactic radiosurgery, a minimally invasive treatment delivering high doses of radiation to a well-defined target, has transformed interdisciplinary treatment paradigms since its inception. This study chronicles its adoption and evolution for brain cancer and tumors globally.

Methods

A systematic literature review of SRS-focused articles from 2000 to 2023 was conducted. Literature impact was evaluated using citation counts and relative citation ratio scores. Extracted data were dichotomized between US and international publications.

Results

Out of 5424 articles eligible, 538 met inclusion criteria reporting on 120,756 patients treated with SRS for brain cancer and tumors since 2000. Over time, publication rates grew significantly (p = 0.0016), with 56% of principal investigators based in the United States. Clinical articles accounted for 87% of the publications, with the remainder focused on technological advances. Relative to international studies, US publications had larger median samples (74 vs. 58, p = 0.012), higher median citations (30 vs. 19, p < 0.0001) and higher relative citation ratio scores (1.67 vs. 1.2, p < 0.00001). Gamma Knife and LINAC had roughly equal representation in US and international publications. Neurosurgery specialists authored more Gamma Knife-based articles, and radiation oncology specialists authored more LINAC-based papers (p < 0.0001). The most treated tumors were metastases (58%), skull base tumors (35%), and gliomas (7%). Radiographic control was achieved in 82% of metastatic tumor cases, with a 12% median complication rate.

Conclusions

SRS has been widely adopted both nationally and globally and continues to be a growing field. This study corroborates the clinical efficacy of SRS and reinforces its critical role in the multidisciplinary treatment of patients with brain tumors and cancer.

Abstract Image

查看原文本刊更多论文

改变脑肿瘤治疗：放射外科在二十多年来的多学科治疗中的全球影响

立体定向放射外科是一种向明确目标提供高剂量辐射的微创治疗，自诞生以来已经改变了跨学科治疗范式。这项研究记录了全球脑癌和肿瘤的采用和演变。方法对2000 ~ 2023年以srs为重点的文章进行系统的文献综述。文献影响评估使用引用计数和相对引用比率得分。提取的数据在美国和国际出版物之间进行了分类。结果在5424篇符合条件的文章中，538篇符合纳入标准，报告了自2000年以来使用SRS治疗脑癌和肿瘤的120,756例患者。随着时间的推移，发表率显著增长（p = 0.0016）， 56%的主要研究人员在美国。临床文章占出版物的87%，其余的集中在技术进步上。与国际研究相比，美国出版物的中位数样本更大（74比58，p = 0.012），中位数引用率更高（30比19，p < 0.0001），相对引用率得分更高（1.67比1.2,p < 0.00001）。伽玛刀和LINAC在美国和国际出版物中的代表性大致相等。神经外科专家撰写了更多基于伽玛刀的文章，放射肿瘤学专家撰写了更多基于linac的论文（p < 0.0001）。治疗最多的肿瘤是转移瘤（58%）、颅底肿瘤（35%）和胶质瘤（7%）。82%的转移性肿瘤病例获得了影像学控制，中位并发症发生率为12%。结论SRS在国内外已被广泛采用，并将成为一个不断发展的领域。本研究证实了SRS的临床疗效，强化了其在脑肿瘤及肿瘤患者多学科治疗中的重要作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.